Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago.I plan on writing up some data, along with a wrap-up or two after the conference, so stay tuned for my coverage. If you see me at ASCO this weekend, don't hesitate to say hello!I'll be focusing on some of the larger names in the industry. Here's some of the data I'm looking at:More than 5,000 research abstracts will be presented or published at ASCO, which starts on Friday and lasts until Tuesday. There w ...

The major market indexes keep hitting new highs, but these stocks haven't participated in the bull run.Does the stock market feel overbought to you? After watching the benchmark S&P 500 index climb about 28% over the past year, nobody can blame value-conscious investors for thinking twice before buying any stocks these days.The benchmark index is way up, but not all of its components have participated in the rally. Shares of Pfizer (PFE 0.66%) and Walgreens Boots Alliance (WBA 0.50%) have been beaten down m ...

JHVEPhoto A couple of weeks ago, this blog’s technician (Gary S. Morrow) shot me a message, noting that he thought Pfizer (NYSE:PFE) was putting in a longer-term bottom. The above chart, which is a monthly chart of PFE using Worden’s TC2000 Gold (and is not the chart that was sent to me), shows the stock “oversold” on a monthly basis, and not that many stocks ever get truly oversold on a monthly basis, so you can say it’s an important technical indicator when it happens. Looking at the bottom third of ...

JHVEPhoto Pfizer (NYSE:PFE) (NEOE:PFE:CA) hasn't been a favorite biopharma play due to the unsustainable Covid boost, leading to a period of sales declines. The stock appears to have hit bottom and could get a push higher from the bird flu fears, though the company is now too focused on cost cuts. My investment thesis is now slightly bullish on the stock due to the cheap valuation. Source: Finviz Hitting Bottom The key to the investing story is removing the risk of additional Covid sales downside. Pfi ...

Core Viewpoint - Pfizer, as a leading pharmaceutical company, is generating substantial cash flow, primarily driven by its innovative medicines and COVID-19 products, allowing it to return significant value to shareholders through dividends and potential future increases in payouts [1][2]. Group 1: Dividend Payments - Pfizer announced a dividend increase to $0.42 per share, up from $0.41, indicating a commitment to returning value to shareholders [2]. - The company is expected to distribute approximately $9.52 billion in dividends this year, based on its outstanding shares of about 5.67 billion [2]. Group 2: Share Repurchase and Stock Performance - Pfizer's existing share repurchase authorization is $3.3 billion; however, the company does not plan to repurchase shares this year, which may impact the stock's performance [2]. - The stock currently offers a yield of 5.8%, making it attractive for investors seeking income [3]. Group 3: Revenue and Growth Potential - Despite a decline in total sales, excluding COVID-19 products and currency fluctuations, Pfizer's first-quarter revenue increased by 11% year over year, indicating underlying growth potential [3]. - With the worst impacts of COVID-19 behind, Pfizer's profitability is expected to improve significantly over the coming years, making it a favorable addition to diversified investment portfolios [3].

Going against the grain here looks like a great idea.When looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy. Companies with juicy yields are only worth investing in provided they can support their payouts. We saw just recently that even otherwise solid income stocks with incredible yields can resort to slashing their dividends; that's exactly what happened to Walgreens Boots Alliance and Medical Properties Trust.Not every high-yield stock will suffer this fate, tho ...

These are three solid contenders for your portfolio.It's hard to beat stocks when you're looking to build wealth over many years. Per the research of Wharton professor Jeremy Siegel, stocks have outperformed bonds, gold, and the dollar over more than 200 years.Bonds were the closest competitor, but stocks beat bonds over relatively shorter periods, too; over the 75 years between 1946 and 2021, stocks grew at an average annual rate of 11.3%, versus 5.8% for long-term government bonds. (The long-term annual a ...

Pfizer (PFE) announced that it is launching a new cost-restructuring program to reduce its spending. Spanning across multiple years, the program intends to reduce the company’s costs of goods sold in a multi-phased effort.The first phase of the program, which is focused on operational efficiencies, is expected to save nearly $1.5 billion by the end of 2027. Management expects to start realizing these savings next year.Pfizer expects to incur about $1.7 billion as one-time costs for the first phase of the pr ...

From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 200-day moving average, and this suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support or re ...